CN1893937A - Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity - Google Patents
Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity Download PDFInfo
- Publication number
- CN1893937A CN1893937A CNA2004800379582A CN200480037958A CN1893937A CN 1893937 A CN1893937 A CN 1893937A CN A2004800379582 A CNA2004800379582 A CN A2004800379582A CN 200480037958 A CN200480037958 A CN 200480037958A CN 1893937 A CN1893937 A CN 1893937A
- Authority
- CN
- China
- Prior art keywords
- acid
- compositions
- desired purposes
- weight
- ursolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A material comprising from 30 to 80 % by weight of ursolic acid, from 2 to 25 % by weight of oleanolic acid and from 1 to 68 % by weight of triterpenoic acids other than ursolic acid or oleanolic acid, or derivatives of any of these acids, said percentages being based on total weight of said acids or derivatives and the percentages of said acids or derivatives adding up to 100 %, can be used in the prevention or treatment of hypersensitivity and/or hyper-reactivity.
Description
The present invention relates to the purposes of some materials in prevention or treatment anaphylaxis and/or overresponse.
Anaphylaxis is to be used to describe the term that produces and can cause the adaptive immunity response of inflammatory reaction and tissue injury with excessive or improper form.Usually do not occur anaphylaxis when contacting for the first time, but appear at usually in subsequently the contact with specific antigen.Anaphylaxis is divided into four types, I, II, III and IV type.First three types is antibody-mediated, and the 4th kind mainly by T cell and macrophage-mediated.When IgE responsive alignment environmental antigens such as pollen or house dust, type i allergic reaction takes place and cause having acute inflammatory response as asthma or rhinitis symptom.
Overresponse is airway constriction (Blease etc., the Respir Res.2000 of the feature and the excessive degree of many inflammatory lung diseases; 1 (1): 54-61).Overresponse can be defined as histamine or the excessive non-immune bronchoconstriction response of methacholine that low concentration is sucked.Such bronchus overresponse is the almost constant performance of asthma (American Academy ofAsthma and Allergy, Asthma and Immunology, In The News 2003, Mechanism in bronchial hyperreactivity).
Dai etc., Zhongguo Yao Li Xue Bao, in November, 1988,9 (6): 562-5 has described by oleanolic acid and has suppressed anaphylaxis.JP-A-3287530 (Snow Brand MilkProd Co Ltd) discloses and has contained ursolic acid or the ketone group ursolic acid immunosuppressant as active component.
Raphale etc., Phytomedicine, 10,483-499,2003, glycyrrhizic acid, ursolic acid, oleanolic acid and Nomilin are disclosed to immune effectiveness.Described chemical compound has improved the antibody generation, describes ursolic acid, oleanolic acid and Nomilin simultaneously and is used to suppress delayed hypersensitivity.
Other lists of references of describing the healthy effectiveness of ursolic acid and oleanolic acid comprise US4752606, JP09/040689, JP09/067249, JP09/020,674, CN1085748, JP1039973, JP03/287531, JP03/28743, EP774255; JP07/258098, JP07/048260, JP01/132531, FR2535203 and JP1207262.
EP-A-1161879 has described that to contain weight ratio be 1: 99 to 99: 1 the ursolic acid and the mixture of oleanolic acid, wherein mixture contains the natural nonpolar and/or low-molecular-weight composition that is lower than 20wt%, as the natural extract existence of sky ursolic acid and oleanolic acid.
EP-A-1123659 has described fat blend, has the compositions that contains ursolic acid and oleanolic acid.Compositions display high percent crystallization in massecuite.
Have been found that the compositions that contains ursolic acid and oleanolic acid and other triterpenic acids (triterpenoicacid) (sometimes being also referred to as triterpenic acid (triterpenic acid)), its extract that can be used as natural material obtains, and can be used for the treatment of and/or Polyglucan reaction and/or overresponse.
According to the present invention, in aspect first, provide to contain and had an appointment 30 to about 80% weight ursolic acid, about 2 to about 25% weight oleanolic acid and about 1 to the triterpenic acid of about 68% weight except that ursolic acid and oleanolic acid, or the material of any derivant is used for preventing or treating the purposes of anaphylaxis and/or hyperreactive compositions in these acid in preparation, described percentage ratio is based on the gross weight meter of described acid or derivant, and the percentage ratio of described acid and derivant adds up to 100%.The invention still further relates to and be used for prevention or treatment anaphylaxis and/or hyperreactive described material.
Another aspect of the present invention is prevention or treatment anaphylaxis and/or hyperreactive method, comprise the material that effective dose is provided to the patient that these needs are arranged, described material contains has an appointment 30 to about 80% weight ursolic acid, about 2 to about 25% weight oleanolic acid and about 1 to the triterpenic acid of about 68% weight except that ursolic acid and oleanolic acid, or any derivant in these acid, described percentage ratio is based on the gross weight meter of described acid and derivant, and the percentage ratio of described acid and derivant adds up to 100%.
What the present invention also comprised is the method that reduces the IgE level, comprise the material that edible for patients is provided to the patient, this material contains has an appointment 30 to about 80% weight ursolic acid, about 2 to about 25% weight oleanolic acid and about 1 to the triterpenic acid of about 68% weight except that ursolic acid and oleanolic acid, or any derivant in these acid, described percentage ratio is based on the gross weight of described acid and derivant, and the percentage ratio of described acid and derivant adds up to 100%.Therefore, in one embodiment, the present invention relates to treat anaphylaxis and/or overresponse by the IgE level that reduces the patient.
It is of the present invention that on the one hand to be ursolic acid or derivatives thereof or oleanolic acid or derivatives thereof or its mixture again be used for preventing or the purposes of the over-drastic compositions of therapeutic response in preparation.The invention still further relates to and be used for prevention or the over-drastic ursolic acid or derivatives thereof of therapeutic response or oleanolic acid or derivatives thereof or its mixture.
The present invention also provides prevention or the over-drastic method of therapeutic response, comprises that patient to needs provides ursolic acid or derivatives thereof or oleanolic acid or derivatives thereof or its mixture of effective dose.
Anaphylaxis is allergy normally.Preferably when the patient took (preferred mammal, more preferably people), described material had the effectiveness that reduces the IgE level.Think the reduction that the reduction of this IgE level causes allergic reaction at least in part.
The preferred effectiveness of material of the present invention is inhibition or prevents bronchial contraction, for example in treatment asthma.Material of the present invention can alleviate air flue to sucking the excessive response of stimulus object and virus and temperature change.
The present invention can relate to anaphylaxis and/or hyperreactive treating and/or preventing.The symptom that can prevent and/or treat according to the present invention comprises asthma, cough (comprise dry cough, itch and cough cough with excessive phlegm), asthma and watery nasal discharge.
The present invention preferably relates to the oral or edible of material and/or compositions.Therefore material and/or compositions preferably are suitable for oral.
Material of the present invention can be mixed with multiple different product form, comprise for example pharmaceutical composition, food or food supplement.Preferably, pharmaceutical composition, food or food supplement comprise the total amount of ursolic acid and oleanolic acid with the dosage in 0.02g to 20g/ sky.Compositions can contain one or more other being used for the treatment of and/or Polyglucan or hyperreactive composition.
Compositions of the present invention can also contain one or more and be selected from the other composition of puting together linoleic acid (CLA), fish oil, puting together trienic acid and composition thereof.
Preferred composition according to the present invention is a food.Food comprises liquid (for example beverage) and solid.Suitably, with packaging for foodstuff and be labeled as food.General food can mix the material of the present invention of appropriate amount.
Pharmaceutical composition can be, for example, tablet, pill, capsule, granose form, many granules comprise: granule, pearl, ball and microcyst granule; Powder, elixir, syrup, suspension, emulsion and solution.Preferred product form is tablet, capsule, solution and emulsion.Pharmaceutical composition will contain acceptable diluent or carrier on the materia medica.Pharmaceutical composition preferably is suitable for parenteral (for example oral).Oral compositions can be solid or liquid form and the form that can adopt tablet, powder, suspension and syrup.Randomly, compositions contains one or more flavoring agents and/or coloring agent.Be applicable to that acceptable carrier is that pharmaceutical field is known on the materia medica of such compositions.Pharmaceutical composition of the present invention can contain the material of the present invention of 0.1-99% weight.Usually prepare pharmaceutical composition of the present invention with unit dosage form.
An example again of the present composition is a food supplement, and as the form of soft gel or hard capsule, it comprises the cover material that is selected from gelatin, starch, modified starch, starch derivatives such as glucose, sucrose, lactose and fructose.Cover material can be chosen wantonly and contain cross-linking agent or polymerizer, stabilizing agent, antioxidant, the light absorber that is used to protect the photaesthesia filler, antiseptic etc.Preferably, the unit dose of the present composition is 1mg to 1000mg (more preferably 100mg to 750mg) in the food supplement.
Preferred food comprises and is selected from following those: margarine, fat continuously or water continuously or the coating of co-continuous, reduce coating, confectionery such as chocolate or the chocolate coating or the chocolate stuffing material of fat or bake stuffing material, ice cream, ice-cream coating, ice cream inclusions, flavoring agent, mayonnaise, cheese, cream substitute, dried soup, beverage, cereal bars, dip, some axle, milk product, clinical nutrition goods and babies ' formula milk powder.Food preferably contains the material of the present invention of 0.001% to 5% weight (more preferably 0.01% to 4%, more preferably 0.1% to 3%, most preferably 0.1% to 2% or 0.1% to 1% weight).
Some used preferred food products comprise material and other mixture of ingredients forms among the present invention, especially as with the mixture of glyceride preferably glycerine three esters.Mixture preferably contains 1 to 99wt%, and more preferably one or more of 5 to 80wt% are selected from the composition of monoglyceride, diglyceride and triglyceride.The glyceride of this mixture part preferably present by the NMR-pulse to shown in the solid fats content measured of temperature destabilised fat, 5 ℃ are 5 to 90,20 ℃ and are 2 to 80 and 35 ℃ and are lower than 15, preferably are lower than 10.
By known NMR-pulse technique destabilised fat is measured solid fats content, this is meant measures the fat of accepting following processing: 80 ℃ of fusings, keep 80 ℃ 15 minutes, be cooled to 0 ℃ and keep 0 ℃ 30 minutes, be heated to and measure temperature and kept this temperature 30 minutes, in this temperature survey N-value.
Preferred mixture is the mixture that contains composition A, B and C, wherein:
A is a material according to the invention,
B has to be higher than 20, preferably is higher than 45, most preferably is higher than the hard fat of 60 N20, and
C has the fat of 40wt% fatty acid at least, and this fatty acid has 18 C atoms and has one to three two key.
Usually the amount of A is higher than 0.1wt%, and preferred 0.1 to 20wt%, and most preferably 0.2 to 10wt%.The amount of B is 8 to 90wt%, and preferred 25 to 75wt%, and most preferably 40 to 70wt%.The amount of C is 0 to 85wt%, and preferred 15 to 65wt%, and most preferably 20 to 50wt%.
In these mixture, fat constituent B is preferably selected from Petiolus Trachycarpi oil; The Petiolus Trachycarpi oil fraction; Cocoa butter equivalent; Palm-kernel oil; The fraction of palm-kernel oil; Hardened vegetable oils such as hardened palm oil; The hardened palm oil fraction; The sclerosis soybean oil; Hardened sunflower oil; Hardened rapeseed oil; Sclerosis soybean oil fraction; The hardened rapeseed oil fraction; The hardened sunflower oil fraction; The mixture of one or more mixture and ester exchange thereof in these oil.
Fat constituent C is liquid oil normally, and is preferably selected from Oleum helianthi; Olive oil; Soybean oil; Oleum Brassicae campestris; The Petiolus Trachycarpi oil olein; Oleum Gossypii semen; The olein fraction of vegetable oil; High oleic acid vegetable oil such as HOSF (=high oleic sunflower oil) and HORP (=high oleic acid Oleum Brassicae campestris); Fish oil; Fish oil concentrate and put together linoleic acid (CLA)-glyceride.
The mixture that comprises composition A as disclosed above, B and C is for having remarkable characteristic in the food that is applied to contain oil phase.
Mixture can also contain other known additives such as antiseptic, coloring agent, stabilizing agent, vitamin and mineral.
Material of the present invention comprises ursolic acid, oleanolic acid and other triterpenic acids, or any derivant in these acid, and the mixture that it is believed that acid provides the advantage of the respective acids that surmounts independent use.Material of the present invention comprises about 30% ursolic acid to about 80% weight, about 2% oleanolic acid and about 1% triterpenic acid except that ursolic acid and oleanolic acid to about 68% weight to about 25% weight, or any derivant in these acid.Triterpenic acid beyond ursolic acid and the oleanolic acid comprises Crataegolic acid.Preferably, material of the present invention comprises about 40% ursolic acid to about 80% (as 40 to 70%) weight, about 5 oleanolic acid and about 10 the triterpenic acids except that ursolic acid and oleanolic acid, or any derivant in these acid to about 50% (as 25 to 50%) weight to about 15% weight.More preferably, material of the present invention comprises about 45 ursolic acids to about 65% weight, about 5 oleanolic acid and about 15 triterpenic acids except that ursolic acid and oleanolic acid to about 50% weight to about 15% weight, or any derivant in these acid.More preferably, material of the present invention comprises about 50 ursolic acids to about 60% weight, about 8 oleanolic acid and about 30 triterpenic acids except that ursolic acid and oleanolic acid to about 40% weight to about 12% weight, or any derivant in these acid.These percentage ratios are based on these sour gross weight meters in the material.Gross weight meter based on material, it is about 30% to 100% weight that material preferably includes total amount, more preferably 30% to 95% weight, more preferably 30% to 90% weight is as ursolic acid, oleanolic acid and other triterpenic acids (or derivatives thereof) of 30% to 70% weight or about 40% to 60% weight.Other compositions of material can comprise triglyceride, polar substances and micro constitutent.
The derivant that is applicable to ursolic acid, oleanolic acid and other triterpenic acids among the present invention comprises chemical compound and the salt that is derived from acid, the activity that it does not have toxicity and do not suppress acid at used content.Suitable derivant comprises that ester is (for example, with the ester of the alcohol formation that comprises 1 to 22 carbon atom, as C
1To C
6Arrcostab) and salt (for example sodium salt or potassium salt).Yet material preferably includes the acid of free acid form.Optional sodium salt with the blended ursolic acid of free acid, oleanolic acid and other triterpenic acids also is preferred.
Preferably, material of the present invention can from peel extract or obtain in addition and preferably have with natural peel the substantially the same ursolic acid and the oleanolic acid ratio that exist.Suitably obtain peel from the fruit that is selected from Fructus Mali pumilae, Cranberries, Fructus Canarii albi, Fructus Vitis viniferae or its mixture.In order to improve taste characteristics, described in EP-A-1161879, handle raw material.Therefore the preferred triterpenic acid that from peel, obtains in the raw material of the present invention.
Preferably obtain material of the present invention by following method: comprise with organic solvent (mixture of preferred acetone or acetone and water) handle peel (randomly exsiccant and randomly water and/or 25 ℃ and etc. the immiscible solvent of mole of water such as hexane wash), removing desolvates forms extract, randomly dry and randomly be further purified exsiccant extract.Be further purified step and comprise, for example: be dissolved in dry extract in the acetone and filter resulting solution, after this remove and desolvate; And wash exsiccant extract (for example, at high temperature for example 40 to 90 ℃) with water.
The derivant that can correspondingly prepare acid.For example, the material that can prepare the sodium salt that contains ursolic acid, oleanolic acid and other triterpenic acids by the following method: at suitable concn (as 0.1 to 1M, preferred 0.4 to 0.6M) alkaline sodium salt (for example, sodium hydroxide) exist down, with organic solvent (mixture of preferred acetone or acetone and water) handle peel (randomly exsiccant and randomly water and/or 25 ℃ and etc. the immiscible solvent of mole of water such as hexane wash).Remove any solid (for example) from the gained mixture, and form serosity except that desolvate (for example, under vacuum) preferably at about 60 ℃ by filtering.Resulting serosity is filtered once more, and randomly, wash the sodium salt mixt that forms as residue with water, can be dried and randomly be further purified.
All publications, patent and patent application are hereby incorporated by.Although in description before, the present invention has been described for its specific preferred embodiment, and listed many detailed contents for illustrative purposes, those skilled in the art know that the present invention allows that other embodiment and specific details described herein can considerably change and do not break away from basic principle of the present invention.
Following non-limiting example has illustrated the present invention and has limited its scope never in any form.In embodiment and the whole description, unless otherwise noted, all percentage ratios, umber and ratio are all by weight.
Embodiment
Embodiment relates to accompanying drawing, wherein:
Fig. 1 is for the group before or after handling according to the present invention, air pressure overall volume tracing and improve the curve to the raising of methacholine concentration of increasing of pause (enhanced pause).
Fig. 2 is bar diagram, shows four IgE serum levels before or after not exciting with ovalbumin (OVA) on the same group, and matched group and three are according to of the present invention group.
Fig. 3 is bar diagram, has shown material according to the invention, and it is the sodium-salt form of Fructus Mali pumilae extract, compared with the control, is alleviating bronchus to the effectiveness in the methacholine overresponse.
Embodiment 1
Will about 25000kg apple pomace (mainly being Pi Hehe) dryly in 100-150 ℃ baking oven produce about 6000kg and contain the dry fruit slag that is lower than 10wt% moisture. The product of drying is ground to and can by the screen cloth of 20mm, stays most of complete kernel.
In ten step countercurrent extractors, carry out drying/grind the extraction of pomace with 50-55 ℃ hot acetone until remove and be higher than 95% acetone extractable. In one pair of thin layer evaporator, remove acetone under the vacuum. Simultaneously, add the aqueous suspension that pure water makes the non-polar compound that comprises triterpenic acid.
Make resulting 5 to the 15% solid water slurry coolings that contain, the centrifugal then water of removing most of existence obtains wet cake.Remove most of residual polar compound that comprises sugar with other hot pure water rinsing filter cake.
The cake that will wet is suspended in it can be moved by pump, and spray drying is to producing thin dry powder (being lower than 0.5% moisture) then.Thin dirt in the filter bag and remaining product are merged.This obtains the dried Fructus Mali pumilae extract of 617kg.
For further purification, the 120kg extract is dissolved in 40 ℃ of acetone of 9600kg.Then, add the Norit SA4 activated carbon (9kg) of 7.2kg and mixture stirred 6 hours at 47 to 53 ℃.By removing activated carbon in conjunction with Arbocel 00 filter of two continuous 1-3 μ m filter plates.
In a pair of thin layer evaporator, remove acetone under the vacuum.Simultaneously, add the aqueous suspension that pure water makes the non-polar compound that comprises triterpenic acid.
Then its spray drying is made thin dry powder (＜0.5% moisture).Thin dirt in the filter bag and remaining product are merged.Obtain the pure extract of 67.2kg altogether.
Resulting product contains the oleanolic acid of the ursolic acid of 55% weight of having an appointment, about 10% weight and other triterpenic acids of about 35% weight, based on these sour gross weight meters in the material.Triterpenic acid accounts for about 49% weight of product weight, based on the gross weight meter of material.
Embodiment 2
The patient who suffers from allergic asthma is characterised in that the existence of allergenic specific IgE antibody and the existence of non-specific airway hyperreactivity.Use Fructus Mali pumilae marc extract that two mouse model researchs contain ursolic acid to IgE level (embodiment 3) and air flue effectiveness (embodiment 2) to the generation of methacholine overrespond
Obtain the BALB/cByJIco mice.In case obtaining animal weighs it and labelling.Before experimental program begins 7-4 days, feeding animal contained the meals of active component.
Experimental program 1: to the effectiveness of airway hyperreactivity
Animal (every group of n=14) is fed the meals that mix following material:
Group 1: do not add
Group 2: dosage is 0.75% the ursolic acid and the sodium salt of oleanolic acid
The extract of the embodiment 1 of group 3:2.5%
The extract of the embodiment 1 of group 4:4%
0-14 days: administration every other day, administration seven times, each peritoneal injection 10 μ g ovalbumins (OVA).
The 27th day: collect blood and be used to measure the specific immunoglobulin of OVA-.
The 31st day: measure the substrate reaction of air flue to methacholine.
38-45 days: administration every other day totally eight days, excited by sucking with 2mgOVA/ml saline.
The 46th day: measure the substrate reaction of air flue to methacholine.
The results are shown among Fig. 1.
Use air pressure overall volume tracing and as airway obstruction exponential raising the increasing of (Penh) that pause, measure airway reactivity.From the result of Fig. 1, be clear that control mice (group 1) has produced the air flue overrespond to the methacholine that improves dosage.In addition, it will be clear that the generation that has suppressed airway hyperreactivity with pure Folium Vaccinii vitis-idaeae hydrochlorate processing (group 2) and 2.5% and 4% extract-treated (organizing 3 and 4 separately) consumingly.
This embodiment has shown that extract according to the present invention has alleviated the airway hyperreactivity of asthma mouse model.
Embodiment 3
Studied the effectiveness of extract to the allergenic specific IgE level.
Use the big male BALB/c mouse of SPF-of 6 weeks.Used four groups under study for action:
I) contrast
The ii) meals of 0.5%UA extract
The iii) meals of 1%UA extract
The iv) meals of 2.5%UA extract
Use following experimental program:
The the 0th to 7 day: with OVA (anaphylactogen)+Alumen i.p. sensitization
The 20th day: before exciting, measure IgE
21st, 24,27 days: excited 3 times at 3 days with OVA-aerosol or saline
The 28th day: measure the IgE after exciting
The results are shown among Fig. 2.
From Fig. 2, be clear that excite with OVA after, in all groups, induced specific IgE (difference be before and afterwards).Yet, be clear that also introducing ursolic acid by meals makes the horizontal dose dependent of IgE reduce.
This embodiment has shown that extract according to the present invention has reduced the IgE level in the mouse model.
Embodiment 4
Below be the embodiment that fills gelatine capsule according to the present invention.The extract encapsulate that will produce according to embodiment 1 according to method well known in the art is in gelatine capsule.Resulting encapsulated products contains the mixture of 500mg extract, and the adult can take four every day, each a slice.
Embodiment 5
Below be embodiment according to margarine type coating of the present invention.Make coating according to the method described in the embodiment 14 of WO97/18320.
Oil phase:
Fat blend
*40%
Hymono 7804 (emulsifying agent) 0.3%
Pigment (2% beta-carotene) 0.02%
Amount to 40.32%
*The Oleum helianthi of 87: 13 weight and hard stock (hardstock)
Water (to pH5.1)
Water 55.94%
The extract 0.5% of embodiment 1
Defatted milk powder 1.5%
Gelatin (270 Refined Mercurous chloride) 1.5%
Potassium sorbate 0.15%
Citric acid powder 0.07%
Amount to 59.66%
Embodiment 6
The preparation of triterpenic acid sodium salt
All be dissolved in the acetone of 400ml at the Fructus Mali pumilae extract of room temperature the 40g hexane wash.In about 10 minutes, add the 0.5M NaOH of 290ml and with mixture stir about 20 minutes.Reaction solution is removed acetone by filter paper filtering and under vacuum in 60 ℃.Resulting serosity is filtered by the Buchner filter, and with distillation cold water washing filter cake and in drying at room temperature.
Embodiment 7
The animal effect research
Suffers from the existence that has the chronic inflammatory disease of eosinocyte advantage in the overresponse of existence that the allergic asthma patient is characterised in that allergenic specific IgE antibody, air flue and the air flue.Produced the mouse model (BALB/c) that has with the abundant sign of asthmatic patient similar features.
By the 1st day until the 13rd day every other day 7 times peritoneal injection make mice to ovalbumin (OVA) sensitization and any adjuvant of no use.Subsequently, from the 33rd day to the 40th day, by being exposed to the mice that the aerosol that contains OVA excites these sensitizations.At the 41st day mice is killed.The bronchus overresponse of measuring methacholine at the 41st day.
This research comprises 7 processed group, every group of 14 animals.
Finish to feed by the meals mixed extract and from the 0th day until research.
Tested following group:
Group A1: the sodium salt of Fructus Mali pumilae extract, wherein the triterpenic acid in the meals is 0.85%.
Group A2: the sodium salt of Fructus Mali pumilae extract, wherein the triterpenic acid in the meals is 0.24%.
Group A3: the sodium salt of Fructus Mali pumilae extract, wherein the triterpenic acid in the meals is 0.085%.
Group A4: the sodium salt of Fructus Mali pumilae extract, wherein the triterpenic acid in the meals is 0.05%.
Group B1: the sodium salt that contains ursolic acid and oleanolic acid (Selco) that can buy, wherein these triterpenic acids are 0.85% in the meals.
Group C1: Fructus Mali pumilae extract, wherein the triterpenic acid in the meals is 0.85%.
Group D: contrast.
Make the compositions of group A1 to A4 according to embodiment 6.
Following table has shown the content of triterpenic acid in the composition therefor.
The content of triterpenic acid (%) in the preparation
| Ursolic acid wt% | Oleanolic acid wt% | Other triterpenic acids wt% | The total amount wt% of triterpenic acid | |
| The sodium salt of Fructus Mali pumilae extract (A1-A4) | 65.8 | 11.2 | 14.5 | 91.15 |
| Fructus Mali pumilae extract (B1) | 27.5 | 5.8 | 21.4 | 54.7 |
| The ursolic acid that can buy and the sodium salt of oleanolic acid (C1) | 63.2 | 21.7 | 0.7 | 85.6 |
Fig. 3 has shown this result of experiment.Fig. 3 has proved compared with the control (group D), and the sodium salt of Fructus Mali pumilae extract (group A1) has alleviated the overresponse of bronchus to methacholine.Extract A 1 is the most effective, then is Fructus Mali pumilae extract (C1), then is the salt material (B1) that can buy.For group A1 to A4, there is tangible dose response dependency.Can infer two kinds of Fructus Mali pumilae extracts, salt and non-salt, the dosage with 0.85% in the meals that contain the triterpenic acid combination more has activity than the sodium salt that mainly contains ursolic acid and oleanolic acid that can buy.(the Penh value is that the metric and the methacholine of airway reactivity is the bronchoconstriction agent).Data show by the group A1 illustrational present composition and are better than maximally relatedly having different ursolic acids and oleanolic acid content and/or having the compositions of other triterpenic acids of lower content.
Claims (15)
1. a material is used for preventing or treating the purposes of anaphylaxis and/or hyperreactive compositions in preparation, described material contains the ursolic acid of 30 to 80% weight, the triterpenic acid except that ursolic acid or oleanolic acid of the oleanolic acid of about 2 to 25% weight and 1 to 68% weight, or any derivant in these acid, described percentage ratio is based on the gross weight meter of described acid or derivant, and the percentage ratio of described acid or derivant adds up to 100%.
2. as desired purposes in the claim 1, wherein anaphylaxis is an allergy.
3. as desired purposes in claim 1 or 2, wherein compositions has reduced the level of IgE.
4. as each desired purposes among the claim 1-3, wherein compositions suppresses or prevents bronchial contraction.
5. as each desired purposes among the claim 1-4, wherein compositions is pharmaceutical composition, food or food supplement.
6. as each desired purposes among the claim 1-5, wherein ursolic acid and/or oleanolic acid are the forms of sodium salt or potassium salt.
7. as each desired purposes among the claim 1-6, wherein ursolic acid and/or oleanolic acid are the forms of the ester that forms with the alcohol that comprises 2 to 22 carbon atoms.
8. as each desired purposes among the claim 1-7, wherein compositions comprises the total amount of ursolic acid and oleanolic acid with the dosage in 0.02g to 20g/ sky.
9. as each desired purposes among the claim 1-8, wherein ursolic acid and oleanolic acid extract from peel.
10. purposes as claimed in claim 9, its mesocarp is from the fruit that is selected from Fructus Mali pumilae, Cranberries, Fructus Canarii albi, Fructus Vitis viniferae and composition thereof.
11. as each desired purposes among the claim 1-10, wherein compositions is a food, described food be selected from margarine, fat continuously or water continuously or the coating of co-continuous, reduce coating, confectionery such as chocolate or the chocolate coating or the chocolate stuffing material of fat or bake stuffing material, ice cream, ice-cream coating, ice cream inclusions, flavoring agent, mayonnaise, cheese, cream substitute, dried soup, beverage, cereal bars, dip, some axle, milk product, clinical nutrition goods and babies ' formula milk powder.
12. as each desired purposes among the claim 1-11, wherein compositions is the pharmaceutical composition of tablet, capsule, solution and emulsion form.
13. as each desired purposes among the claim 1-12, wherein compositions is the food supplement of soft gel or form of hard gelatin capsules, and it comprises the cover material that is selected from gelatin, starch, modified starch, starch derivatives such as glucose, sucrose, lactose and fructose.
14. as each desired purposes among the claim 1-13, wherein compositions comprises that one or more are selected from the other component of puting together linoleic acid (CLA), fish oil, puting together trienic acid and composition thereof.
15. ursolic acid or derivatives thereof or oleanolic acid or derivatives thereof or its mixture are used for preventing or the purposes of the over-drastic compositions of therapeutic response in preparation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03258087 | 2003-12-19 | ||
| EP03258087.0 | 2003-12-19 | ||
| PCT/GB2004/005453 WO2005058302A1 (en) | 2003-12-19 | 2004-12-17 | Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1893937A true CN1893937A (en) | 2007-01-10 |
| CN1893937B CN1893937B (en) | 2011-01-12 |
Family
ID=34684630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800379582A Expired - Fee Related CN1893937B (en) | 2003-12-19 | 2004-12-17 | Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110229563A1 (en) |
| EP (1) | EP1694320B1 (en) |
| JP (1) | JP2007514727A (en) |
| CN (1) | CN1893937B (en) |
| AT (1) | ATE400262T1 (en) |
| DE (1) | DE602004014974D1 (en) |
| ES (1) | ES2311177T3 (en) |
| PL (1) | PL1694320T3 (en) |
| WO (1) | WO2005058302A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412775A (en) * | 2010-11-22 | 2017-12-01 | 菲尼克斯生物技术公司 | With the method for Alstonia species or the extract for treating nervous disorders of Luckynut Thevetia Seed species |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3466930T3 (en) | 2013-02-08 | 2022-09-05 | Gen Mills Inc | FOOD PRODUCT WITH REDUCED SODIUM CONTENT |
| KR101645963B1 (en) * | 2014-05-13 | 2016-08-08 | 주식회사한국야쿠르트 | A method for high extraction of ursolic acid from apple pomace and food composition comprising the same as an active ingredient |
| CN104610417B (en) * | 2015-02-16 | 2016-05-11 | 白心亮 | A kind of method of extracting ursolic acid and oleanolic acid from hawthorn |
| MX2020002884A (en) * | 2017-09-14 | 2020-10-05 | Phoenix Biotechnology Inc | Method and improved neuroprotective composition for treating neurological conditions. |
| DE102018217341A1 (en) * | 2018-10-10 | 2020-04-16 | Katjes Fassin GmbH.+Co. Kommanditgesellschaft | SWEET COATED WITH APPLE WAX |
| JP7276745B2 (en) * | 2019-06-14 | 2023-05-18 | 地方独立行政法人青森県産業技術センター | Method for producing apple-derived triterpenoid-containing composition, method for producing ursolic acid, and method for producing oleanolic acid |
| CN112704663B (en) * | 2020-12-18 | 2022-07-19 | 吉林农业科技学院 | Preparation method of loquat leaf ursolic acid cream |
| CN114129572B (en) * | 2021-12-16 | 2023-04-07 | 南开大学 | Pharmaceutical composition for synergistically inhibiting tetrandrine-induced drug-induced liver injury |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03287530A (en) * | 1990-03-31 | 1991-12-18 | Snow Brand Milk Prod Co Ltd | Immunosuppressive agent |
| JPH1112178A (en) * | 1997-06-23 | 1999-01-19 | Dainippon Pharmaceut Co Ltd | Oleanolic acid-based anti-pruritus agent |
| ATE308892T1 (en) * | 2000-06-05 | 2005-11-15 | Loders Croklaan Bv | MIXTURES CONTAINING URSOLIC ACID AND OLEANOLIC ACID |
| ATE295087T1 (en) * | 2001-04-09 | 2005-05-15 | Loders Croklaan Bv | CONCENTRATE OF TRITERPENES |
| JP5081354B2 (en) * | 2001-11-07 | 2012-11-28 | 株式会社ナリス化粧品 | IgE production inhibitor |
-
2004
- 2004-12-17 WO PCT/GB2004/005453 patent/WO2005058302A1/en active IP Right Grant
- 2004-12-17 AT AT04806247T patent/ATE400262T1/en not_active IP Right Cessation
- 2004-12-17 EP EP04806247A patent/EP1694320B1/en not_active Not-in-force
- 2004-12-17 JP JP2006544564A patent/JP2007514727A/en active Pending
- 2004-12-17 PL PL04806247T patent/PL1694320T3/en unknown
- 2004-12-17 DE DE602004014974T patent/DE602004014974D1/en active Active
- 2004-12-17 US US10/583,151 patent/US20110229563A1/en not_active Abandoned
- 2004-12-17 ES ES04806247T patent/ES2311177T3/en active Active
- 2004-12-17 CN CN2004800379582A patent/CN1893937B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412775A (en) * | 2010-11-22 | 2017-12-01 | 菲尼克斯生物技术公司 | With the method for Alstonia species or the extract for treating nervous disorders of Luckynut Thevetia Seed species |
| CN107412775B (en) * | 2010-11-22 | 2021-01-05 | 菲尼克斯生物技术公司 | Method for treating neurological disorders with extracts of Nerium species or Thevetia species |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005058302A1 (en) | 2005-06-30 |
| US20110229563A1 (en) | 2011-09-22 |
| DE602004014974D1 (en) | 2008-08-21 |
| ES2311177T3 (en) | 2009-02-01 |
| JP2007514727A (en) | 2007-06-07 |
| PL1694320T3 (en) | 2008-11-28 |
| EP1694320A1 (en) | 2006-08-30 |
| CN1893937B (en) | 2011-01-12 |
| EP1694320B1 (en) | 2008-07-09 |
| ATE400262T1 (en) | 2008-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1073825C (en) | Food composition containing balancing agent for 'omega'-6 and 'omega'-3 unsaturated fatty acids | |
| CN1468060A (en) | Oil/fat composition | |
| CN1906280A (en) | A oil composition enriched in diglyceride with conjugated linoleic acid | |
| CN1309813C (en) | Oil or fat composition | |
| CN1917894A (en) | Muscular tension-elevating agent | |
| JP2007503827A (en) | A composition containing an ingredient derived from salvia sclare seed as an active ingredient | |
| JP5099808B2 (en) | Composition for improving lipid metabolism | |
| CN1893937A (en) | Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity | |
| JPH0353866A (en) | Lignans-containing food and drink | |
| CN1777420A (en) | Processed fat composition for preventing/ameliorating lifestyle-related diseases | |
| JP3944864B1 (en) | Composition for prevention and improvement of metabolic syndrome | |
| KR101997493B1 (en) | Seasoned laver comprising mushroom extract oil and Manufacturing method thereof | |
| CN102090486B (en) | Method for preparing nutrient linseed oil tea | |
| JP5177676B2 (en) | Fat absorption inhibitor and food and drink using the same | |
| de Lourdes R Giada | Food applications for flaxseed and its components: Products and processing | |
| WO2023063321A1 (en) | Anti-allergic agent | |
| KR102555338B1 (en) | Food Composition Comprising Extract of Lespedeza Cuneate | |
| JP2010105948A (en) | Fatty liver inhibitor | |
| US20230022483A1 (en) | Method for remediating water sources and mixtures formed from the same | |
| KR101178547B1 (en) | Pine nut chocolate and manufacturing method thereof | |
| JPWO2004064830A1 (en) | Oil processing composition for prevention and improvement of lifestyle-related diseases | |
| JP6716208B2 (en) | In-vivo fatty acid composition modifier | |
| JP2004018591A (en) | Fat and oil composition | |
| JP2023140651A (en) | Bowel movement improving composition, method for producing bowel movement improving composition, and method for improving bowel movement | |
| JP2019076019A (en) | Edible shark composition, manufacturing method therefor and foods containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110112 Termination date: 20121217 |